Preclinical Isolated Organ Perfusion System Market to Surpass US$ 589.1 Million by 2027

Global Preclinical Isolated Organ Perfusion System Market, by Type (Isolated Heart Perfusion Systems, Isolated Abdominal Organ Perfusion Systems, Isolated Lung Perfusion Systems and Others), by End User (Industrial Laboratories and CROs and Academic and Government Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 442.8 million in 2020 and is expected to exhibit a CAGR of 4.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Rising cases of transplantations are expected to augment the market growth.

Rising number of transplants are expected to drive the global preclinical isolated organ perfusion system market growth. According to an article published by the Global Observatory on Donation and Transplantation (GODT), in 2018, the total number of kidney, heart, lung, liver, pancreas, and small bowel transplants was around 114.4 and 77.11 in the U.S. and Canada per one million people, respectively.

Global Preclinical Isolated Organ Perfusion System Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus disease (COVID-19) has resulted in over 72.84 million infected individuals worldwide, as of December 17, 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of raw materials from one place to another.

Browse 35 Market Data Tables and 33 Figures spread through 198 Pages and in-depth TOC on “Preclinical Isolated Organ Perfusion System Market – by Type (Isolated Heart Perfusion Systems, Isolated Abdominal Organ Perfusion Systems, Isolated Lung Perfusion Systems and Others), by End User (Industrial Laboratories and CROs and Academic and Government Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”

To know the latest trends and insights prevalent in the global preclinical isolated organ perfusion system market, click the link below:

https://www.coherentmarketinsights.com/market-insight/preclinical-isolated-organ-perfusion-system-market-4351

Rising incidence of cardiovascular diseases is expected to drive growth of the market. For instance, according to an article - Heart Disease and Stroke Statistics-2017, published by the American Heart Association, in January 2017, the number of patients with heart failure (HF) in the U.S. was nearing 6.5 million and is estimated to increase by 46% in the next decade so that there will be more than 8 million adults in the U.S. with heart failure (HF) by 2030.

Key Takeaways of the Global Preclinical Isolated Organ Perfusion System Market:

• The global preclinical isolated organ perfusion system market is expected to exhibit a CAGR of 4.2% during the forecast period owing to rising incidence of chronic kidney diseases. According to Heart Disease and Stroke Statistics-2017 published by the American Heart Association in January 2017, prevalence of chronic kidney disease in adults over 30 years of age is projected to increase to 14.4% in 2020 and 16.7% in 2030.
• Among type, the isolated heart perfusion systems segment held dominant position in the global preclinical isolated organ perfusion system market in 2019 owing to rising cases of cardiovascular disease. According to Heart Disease and Stroke Statistics-2017 published by the American Heart Association, in January 2017, an estimated 92.1 million U.S. adults have at least 1 type of cardiovascular diseases. By 2030, 43.9% of the U.S. adult population is projected to suffer some form of cardiovascular diseases.
• Among end user, the industrial laboratories and CROs segment held the dominant position in the global preclinical isolated organ perfusion system market in 2019 owing to research and development of preclinical isolated organ perfusion systems.
• Key players operating in the global preclinical isolated organ perfusion system market are World Precision Instruments Inc., Radnoti LLC, MDE GmbH, Harvard Bioscience Inc., emka TECHNOLOGIES S.A.S., Danish Myo Technology AS, ADInstruments Pty Ltd. and Experimetria Ltd. among others.